| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B ligand-mediated mechanism that was inhibited by the receptor activator of nuclear factor-B (RANK-Fc) in 13 experiments by 71 ± 12% (P < 0.008). In contrast, myeloma cells did not induce differentiation of peripheral blood mononuclear cells. Myeloma plasma cells cocultured with OCs retained their viability and proliferative activity for >13 weeks. After 14 days in coculture, the plasma cells from 29 patients had higher viability (P < 2 x 10-6), fewer apoptotic cells (P < 4 x 10-15), and a higher bromodeoxyuridine labeling index (P < 0.0006) than controls. Physical contact between OCs and myeloma cells was required for these effects to take place. No differences were observed between OCs from healthy donors and those from myeloma patients. Blocking interleukin 6 activity, while reducing survival of myeloma cells, had no effect on their proliferative activity. These results support data obtained from animal models and clinical observations on the essential role of the microenvironment in tumor sustenance and progression. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
MM plasma cells (PCs) typically reside in and disseminate through the hematopoietic BM. Among the most frequent consequences of accumulation of myeloma cells in the BM is increased osteoclast (OC) activity resulting in lytic bone disease in 
80% of patients. In studies using the severe combined immunodeficiency (SCID)-hu model, in which primary human myeloma cells grow exclusively in and interact with the human microenvironment (7
, 8)
, we have demonstrated that in medullary but not extramedullary disease, survival and growth of myeloma cells depend on OC activity (9)
. These studies highlighted the interdependence of myeloma growth and lytic bone disease, also seen in the 5T murine myeloma (10)
and observed in clinical trials (11
, 12)
.
Under physiological conditions, osteoblasts play a major role in recruitment of OC precursors (pOC) and induction of OC formation via production of chemokines and osteoclastogenic cytokines (13, 14, 15)
. Lytic bone disease in myeloma is characterized by reduced number of osteoblasts on bone surfaces adjacent to myeloma cells (16
, 17)
, suggesting that tumor cells may play a direct role in increasing OC activity through production of key osteoclastogenic factors. Whereas recent studies indicated that MM PCs indirectly induce the formation of OCs through disruption of the balance of osteoprotegerin and the receptor activator of nuclear factor-B ligand (RANKL) in the BM (18, 19, 20, 21)
, other studies suggested that myeloma cells express RANKL (22, 23, 24)
or macrophage inflammatory protein-1
and can directly induce differentiation of OC progenitors into OCs (25)
. This may explain how myeloma cells induce osteoclastogenesis in bone areas highly infiltrated by myeloma cells with reduced number of osteogenic cells. However, a direct effect of primary human myeloma cells on recruitment and differentiation of pOC has not been demonstrated.
Even though the most prominent changes in the cellular makeup of the BM microenvironment associated with myeloma are decreases in osteogenic cells and increases in OC numbers and in microvessel density (16 , 26) , numerous studies focused instead on the interactions between myeloma cell lines or primary MM PCs with BM-derived fibroblastoid stromal cells of mesenechymal origin. These reports demonstrated that myeloma-stroma cell interactions result in modulation of the expression of cytokines (27 , 28) and adhesion molecules (29, 30, 31) in both cell types, disruption of the balance of bone remodeling (18 , 19 , 32) , and protection of myeloma cells from spontaneous and drug-induced apoptosis (33, 34, 35) .
To study the relationship between myeloma cells and OCs, we established an ex vivo culture system and investigated the consequences of freshly purified MM PC interaction with pOC and with active OCs.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-MEM and antibiotic mixture containing penicillin, streptomycin, and neomycin were from Gibco (Grand Island, NY). Fetal bovine serum was from Hyclone (Logan, UT). Recombinant human macrophage colony-stimulating factor (M-CSF) and RANKL were from RDI (Flanders, NJ). Dexamethasone, BrdUrd, 5-fluoro-2'-deoxyuridine (FrdU), and leukocyte acid phosphatase kit for tartrate-resistant acid phosphatase (TRAP) were from Sigma (St. Louis, MO). Antihuman CD138 antibody for immunomagnetic bead separation was from Miltenyi-Biotec (Auburn, CA). Monoclonal antibody to human vitronectin receptor was from Biosource International (Camarillo, CA). Human RANK-Fc was a kind gift from Immunex (Seattle, WA). Cell culture plates were from Becton Dickinson (Franklin Lakes, NJ). Chamber slides were from Nalge Nunc International (Naperville, IL), Transwell inserts were from Costar (Corning, NY), annexin V/propidium iodide detection kit for flow cytometry was from Caltag Laboratories (Burlingame, CA), and immunoperoxidase detection kits were from Vector (Burlingame, CA).
Myeloma Cells.
Myeloma PCs were obtained from heparinized BM aspirates from 48 patients with active myeloma during scheduled clinic visits, from peripheral blood of one patient with PC leukemia, and from one plural effusion. Signed institutional review board-approved informed consent forms are kept on record. Pertinent patient information is provided in Table 1
. The BM, peripheral blood, and plural effusion samples were separated by density centrifugation using Ficoll-Paque (specific gravity, 1.077 g/ml), and the proportion of MM PCs in the light-density cell fractions was determined by CD38/CD45 flow cytometry (36)
. PCs were isolated using CD138 immunomagnetic bead selection and the autoMACs automated separation system (Miltenyi-Biotec, Auburn, CA). PC purity was determined by CD38/CD45 flow cytometry to be routinely 94%. ANBL-6 cells were obtained from the American Type Culture Collection (Manassas, VA). ARP-1 and CAG myeloma cell lines were established in our laboratory. Myeloma cell viability was determined by trypan blue exclusion, and apoptotic cells were enumerated using an annexin V/propidium iodide kit.
|
-MEM supplemented with 10% fetal bovine serum, antibiotics, RANKL (50 ng/ml), human M-CSF (25 ng/ml), and 10 nM dexamethasone (OC medium). After 2–4 days, the cultures were washed three times with fresh media to remove the nonadherent cells. The remaining adherent cells were mononucleated, expressed TRAP and vitronectin receptors, and were considered committed pOC. To generate OCs, OC medium was added, and the cultures were continued for an additional 6–10 days, at which time they contained large numbers of multinucleated OCs with bone-resorbing activity.
Migration Assays.
Chemotaxis assays were performed in duplicates using 5-µm pore size Transwell inserts in 24-well plates. The upper chamber contained 1 x 105 pOC in 0.3 ml of OC medum. The bottom chambers contained 0.7 ml of conditioned media from 48-h cultures of purified myeloma cells (106 cells/ml) or fresh medium in control wells. After 3 h at 37°C, the filters were removed, fixed in 10% phosphate-buffered formalin for 10 min, and stained for TRAP. The number of pOC in five nonoverlapping 0.5-mm2 areas of the lower surface of the filter was determined microscopically. In four experiments, 1 x 106 purified MM PCs in 1 ml of M-CSF-containing media were placed in the lower chambers. After 7 days in culture, the inserts were removed, 1 ml of fresh M-CSF-containing media was added, and culture was continued for an additional 7 days, after which the number of multinucleated (3 nuclei) TRAP-positive OCs was determined.
OC Precursor Differentiation Assay.
Experiments were performed in duplicates in 24-well plates. Freshly obtained unstimulated MM PBMCs (1 x 106 cells/well) or committed pOC were cultured alone or with 0.5–1 x 106 purified MM PCs (cocultures) for 7–14 days in -MEM supplemented with human M-CSF (25 ng/ml) but without RANKL. The number of TRAP-positive multinucleated OCs in each well was counted using a phase-contrast microscope.
Myeloma PCs and OC Cocultures.
OCs were washed three times with PBS to detach and remove the nonadherent cells. Purified MM PCs (0.5 x 106 cells/ml in OC medium supplemented with M-CSF and RANKL but lacking dexamethasone) were cultured alone or added to OCs in duplicates in 24-well plates (1 ml/well) for 14 days. In 12 experiments, MM PCs were placed in 0.45-µm pore size Transwell inserts in wells containing OCs (noncontact cultures). In seven additional experiments, MM PCs were cultured with media conditioned by OCs or by MM PC and OC cocultures. At the end of each experiment, MM PCs were counted, and the media were removed and kept frozen at -20°C for additional studies as indicated below. Portions of myeloma cells from one replicate were processed for assessing BrdUrd labeling index (LI) and annexin V binding, and the other replicate was used for measuring [3H]dThd incorporation.
In other experiments, MM PCs were cultured alone or with OCs in 30-mm-diameter culture plates (3 ml/plate). After each 3–4 weeks of culture, the myeloma cells were transferred into plates containing freshly prepared OCs, and cultures were continued for up to 13 weeks. Cell numbers, viability, and annexin V binding were determined at weekly intervals.
OC Activity Assays.
The ability of OCs generated from PBMCs and MM PBMCs to resorb bone and form resorption pits was tested using bovine bone slices (a kind gift from Dr. R. L. Jilka; University of Arkansas for Medical Sciences) and BD BioCoat Osteologic (BD Biosciences, Bedford MA) bone resorption assay. Briefly, pOC were collected by incubation on ice with cold PBS for 10 min, followed by incubation with 10 mM EDTA in PBS for 10 min at 37°C. Cells (1 x 105) in 100 µl of -MEM supplemented with OC media were added onto the bone slices, and mineralized discs were placed in a 24-well plate and allowed to adhere to the bone slices and discs at 37°C for 1 h. After 7–14 days of continuous incubation with OC media, resorption pits on mineralized discs were visualized according to the manufacturer’s instructions. Bone slices were treated with bleach solution for 5 min, washed with water, and lightly stained with 1% toluidine blue. Images of resorption pits were taken using Nikon eclipse 450 microscope. For testing the ability MM PCs to induce formation of functional OCs, pOC were incubated with or without MM PCs on mineralized discs in 1 ml of fresh media containing M-CSF but lacking RANKL and dexamethasone or with complete OC media containing M-CSF, RANKL, and dexamethasone (positive controls).
Immunohistochemistry.
Cytospin slides of myeloma cells (40,000 cells/slide) or chamber slides with pOC and OCs were fixed with 10% phosphate-buffered formalin for 20 min, thoroughly washed, and boiled in citrate buffer in a microwave oven for antigen retrieval. After peroxidase quenching with 3% hydrogen peroxide for 10 min, the slides were incubated with monoclonal antibodies against human vitronectin receptor (5 µg/ml) or RANKL (5 µg/ml) for 60 min. The assays were completed using Vector’s immunoperoxidase kit and counterstaining with hematoxylin.
BrdUrd LI.
BrdUrd and FrdU (20 and 2 µM final concentrations, respectively) were added to cultures of myeloma cells alone or to cocultures for 2 h. Myeloma cells were then collected, and cytospin slides were prepared (40,000 cells/slide) and fixed in 10% phosphate-buffered formalin for 20 min. Duplicate slides were treated with 5 N HCL for 15 min and with 3% hydrogen peroxide for 10 min before incubation with monoclonal antibody against BrdUrd (5 µg/ml). BrdUrd incorporation was detected using Vector’s immunoperoxidase kit, and cells were lightly counterstained with hematoxylin. BrdUrd LI was calculated as the percentage of positive cells out of 500 cells in each duplicate slide.
Cell Proliferation Assay.
Cell proliferation was assessed by the addition of 0.5 µCi [3H]dThd/well during the last 6 h of a 14-day culture. The cells were then harvested onto glass fiber filters with an automatic cell harvester (Molecular Devices Corp., Sunnyvale, CA), and incorporation was measured using a TRI-CARB 1600TR scintillation analyzer (Packard Instrument Co., Meriden, CT). Media taken from culture of OCs alone were used as background.
Phagocytosis by OCs.
CAG and ARP1 myeloma cell lines were incubated with 10-6 M dexamethasone for 5 days to induce cell death. The cells were then stained with trypan blue (diluted 1:1 with PBS) for 10 min and washed five times with 30 ml of PBS, resuspended in OC media, and added onto OC cultures in 8-well chamber slides (1 x 105 cells/well). Phagocytosis of dead myeloma cells by OCs was observed under a light microscope 4–24 h later.
Statistical Analysis.
Unless indicated otherwise, all values were expressed as mean ± SE. The effect of myeloma cell conditioned media on migration of pOC was evaluated using the nonparametric Mann-Whitney test. Student’s paired t test was used to test the effect of MM PCs on differentiation of freshly obtained MM PBMCs and pOC and to evaluate the effect of different culture conditions and treatments on myeloma cell numbers, viability, apoptosis, and proliferation.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Of these, >90% were mononucleated cells, and the rest were small, multinucleated cells. Furthermore, pOC whose media were changed after 2–4 days of culture in complete osteoclastic media to osteoclastic media lacking RANKL and then cultured for an additional 6–21 days remained largely mononucleated and did not form resorption pits on thin mineralized discs (Fig. 1D)
. However, when cultured for an additional 6–10 days in RANKL-containing media, pOC differentiated into large, multinucleated OC-like cells (Fig. 1C)
that similarly formed resorption pits on thin mineralized discs (Fig. 1E)
and bone slices (Fig. 1F)
. In a preliminary study, inoculation of pOC into irradiated human bone in our SCID-hu model (7)
resulted in loss of human bone density, confirming that the pOC injected indeed differentiate to mature, multinucleated, functional OCs (data not shown). In seven randomly selected experiments, the number of TRAP-positive multinucleated OCs was 426 ± 156 (mean ± SD)/well in 24-well culture plates. All OC cultures were devoid of fibroblast-like cells. The OCs remained viable for more than 30 days. The pOC were used to test the effect of myeloma cells on migration and differentiation, whereas cultures of mature OCs were used to test their effect on myeloma cell growth and survival.
|
). To test whether these were functional OCs, in three experiments (pOC alone, MM PCs alone, and pOC plus MM), PCs were cultured on thin mineralized discs in OC media without dexamethasone and RANKL. Only the multinucleated cells induced by MM PCs in these cultures formed resorption pits (Fig. 2F)
and hence were functional OCs, whereas myeloma cells alone (Fig. 2D)
or pOC cultured without MM PCs (Fig. 2E)
on mineralized discs did not form resorption pits.
|
. Addition of RANK-Fc to 13 cultures inhibited MM PC-induced OC formation in 12 of the 13 experiments by 16–100% (median, 90%) and had no inhibitory effect in one experiment (P < 0.008; Fig. 3E
).
|
, myeloma cell conditioned media from nine patients increased migration of pOC by 1.6–4.2-fold over that seen in control wells [127 ± 37 (mean ± SD); P = 0.01].
|
).
Growth of Myeloma Cells in Coculture with OCs.
To investigate whether OCs affect survival and growth of myeloma cells, freshly purified MM PCs from 29 patients were cocultured with cultured OCs from 17 myeloma patients for 14 days. Because of logistic considerations, the myeloma cells and OCs in each coculture were not from the same patient. Purity of the myeloma cells used for these experiments was 94%, and their viability was 94%. Six randomly selected samples contained 25 ± 6% annexin V-positive MM PCs. Unlike their tight adherence to stromal cells, MM PCs did not adhere to the OCs and were easily recovered form cocultures by gentle pipetting (Fig. 5A)
. The nonadherent cells recovered after 14 days of coculture with OCs contained 95% myeloma cells (Fig. 5B)
. Although the total number of myeloma cells recovered from cocultures was 33% lower than that from cultures of myeloma cell alone (P < 0.000002), their viability was significantly higher (95% versus 38%; P < 0.0000002), and their apoptotic rate was significantly lower (22% versus 70% by annexin V; P < 4 x 10-15) than those of myeloma cells cultured alone (Table 2
; Fig. 6A
). Myeloma cells in cocultures with OCs also had higher proliferation rates as indicated by BrdUrd LI (1.3 ± 0.2 versus 0.3 ± 0.1; P < 0.0006; Fig. 6B
) and by [3H]dThd incorporation (5502 ± 1822 versus 1878 ± 883 cpm; P < 0.03). In all experiments, MM PCs in the cocultures produced a higher amount of monotypic immunoglobulins (data not shown). OCs generated from healthy donors were equally supportive of MM PC growth and survival as those generated from PBMCs from myeloma patients. These results are summarized in Table 2
. In some experiments, cocultures were maintained for up to 13 weeks. Although the total numbers of myeloma cells in the cocultures were gradually decreased over time, their viability was consistently >95% throughout the experimental period (data not shown).
|
|
|
demonstrated that OCs indeed removed apoptotic and dying myeloma cells by phagocytosis, confirming previous reports (37
, 38)
. The phagocytic activity of OCs did not affect their viability or their ability to support myeloma cell growth and survival.
To capture the heterogeneity among OCs and MM PCs from different patients, we cocultured myeloma cells from several patients with OCs from one patient (Fig. 7A)
and OCs from different patients with the same MM PCs (Fig. 7B)
. Whereas the effects of OCs on MM PCs from different patients varied widely, myeloma cells from individual patients responded similarly to different OCs, suggesting between-patient heterogeneity in MM PCs but not in OCs.
|
). Viability in the noncontact culture was reduced by 52% compared with cocultures (P < 0.001), annexin V binding was increased 3.7-fold (P < 0.0001), BrdUrd LI was reduced by 46% (P < 0.05), and [3H]dThd uptake was reduced by 58% (P < 0.002) in the noncontact cultures. The number of viable tumor cells in the noncontact cultures was 33% lower than that in cocultures (P < 0.003). These values were not significantly different from those obtained from myeloma cells cultured alone. Similar results were obtained when myeloma cells were cultured with OC conditioned media or with OC-myeloma cell coculture conditioned media. These results indicate that soluble factors alone are not sufficient to support the survival and proliferation of myeloma cells in the cocultures.
|
, blocking IL-6 activity reduced the number of viable primary MM PCs by 30% (P < 0.0001) and reduced [3H]dThd incorporation, although not reaching significance, by 22%. Whereas blocking IL-6 activity had no effect on the BrdUrd LI, annexin V binding increased in treated cells by 78% from 18 ± 2% in control cells, suggesting that IL-6 acts as an antiapoptotic rather than a growth factor in this long-term coculture system.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, transforming growth factor ß, and IL-1 (41
, 42)
. Preliminary results from the SCID-hu model show high expression of RANKL, IL-6, stromal cell-derived factor-1 (SDF-1), and hepatocyte growth factor (HGF) by myeloma-associated microvessels (data not shown).
MM PC-induced differentiation of pOC was RANKL mediated, as evidenced by the inhibitory effects of RANK-Fc. Whether myeloma cells express RANKL has been controversial. Whereas some studies failed to detect RANKL expression by myeloma cells in patients’ BM biopsies and aspirates using reverse transcription-PCR, in situ hybridization, and immunohistochemistry (18, 19, 20)
, others demonstrated that patients’ myeloma PCs (23
, 24)
and murine 5T2 cells (22)
do express RANKL. We found expression of RANKL by myeloma PCs after coculture with OCs in seven of eight experiments by immunohistochemistry. These results demonstrate that in addition to sequestering osteoprotegerin (21)
, affecting osteoclastogenesis via macrophage inflammatory protein-1 production (25
, 43)
, and modulating expression of these cytokines by cells in the BM microenvironment (18
, 19)
, myeloma cells act directly on pOC via RANKL to promote OC formation (24)
.
The close association between myeloma cell growth and OC activity has been gleaned clinically (11 , 12) and has been demonstrated in our SCID-hu model for primary myeloma (9 , 18) , in the ARH77 xenograft model (18 , 44) , and in the 5T2 murine model (10) . The OC/myeloma cell coculture experiments clearly demonstrate the ability of OCs to support long-term survival and proliferation of primary MM PCs. OCs from myeloma patients and from healthy donors were equally as effective and similarly supported myeloma cells from all patients. Although myeloma cells did not firmly adhere to OCs, cell-cell contact was essential, as demonstrated in noncontact experiments and using media conditioned by OCs or OC-myeloma PC cocultures. This indicates that soluble factors release by OCs alone or after their direct interaction with MM PCs are insufficient to promote myeloma cell growth and survival. Taken together with the clinical reports and the data from the experimental models, these results underscore the critical role that OCs play in sustaining the myeloma disease process.
Previous studies reported that BM stromal cells supported survival and growth of primary human myeloma cells (45 , 46) and that BM mesenchymal cells from patients with myeloma abnormally expressed adhesion molecules and cytokines, suggesting that these changes are required to promote myeloma (47) . Our study differs from these reports in several key features; in contrast to BM stroma that consists of an ill-defined mixture of differentiated and undifferentiated cells of mesenchymal and hematopoietic origin (48) , we demonstrate the ability of a single cell lineage to support sustained survival and proliferation of myeloma PCs. Additionally, we report that OC cultures from healthy donors are equally as effective in sustaining myeloma cells as those derived from myeloma patients. In contrast to cultures with BM stromal cells, myeloma PCs do not adhere tightly to OCs, the MM PC:OC ratio is very high (estimated ratio, 1000:1), probably more akin to the ratio in vivo, suggesting that some intercellular communication between myeloma PCs in contact with OCs and other myeloma PCs might occur. The OCs actively phagocytized dying myeloma cells, explaining the lower number of MM PCs recovered from cocultures compared with control cultures.
Whereas we find IL-6 production by both MM PCs and OCs, IL-6 production in MM PC/OC cocultures was not up-regulated, in contrast to MM PC/stromal cell cocultures (27 , 49 , 50) . IL-6 has been reported to be a central myeloma growth factor (51, 52, 53, 54) and to protect MM PCs from spontaneous, drug-induced (33 , 55 , 56) , and Fas-induced apoptosis (57) . Inhibition of IL-6 signaling for 14 days resulted in a 78% increase in apoptotic cells and a 33% reduction in viable cell number but had no effect on myeloma cell proliferation, indicating that IL-6 has antiapoptotic activity in myeloma with no effect on MM PC proliferation. The large number of viable MM PCs in the anti-IL-6 + anti-IL-6 receptor-treated cultures may suggest that IL-6-mediated gp130 signaling was not completely inhibited or that other gp130 activating cytokines are present. Alternatively, it is possible that other survival mechanisms, such as the Ras/mitogen-activated protein kinase pathway, have been activated (58) .
The data presented here demonstrate that myeloma PCs directly induce osteoclastogenesis through RANKL. Osteoclasts, in turn, support survival and proliferation of myeloma cells in a mechanism that is still under investigation. Our findings lend support to observations from clinical trials and from animal models on the central role of OCs in sustaining the disease.
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Shmuel Yaccoby, Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot #776, Little Rock, Arkansas 72205. Phone: (501) 686-5274; Fax: (501) 686-6442; E-mail: YaccobyShmuel{at}UAMS.EDU
Received 4/24/03. Revised 12/22/03. Accepted 1/14/04.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 100: 4615-21, 2002.B ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res, 63: 5438-45, 2003. is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor B ligand. Blood, 97: 3349-53, 2001.4ß1-integrin enhances production of osteoclast- stimulating activity. Blood, 96: 1953-60, 2000.. J Dent Res, 81: 11-6, 2002.B ligand in vascular endothelial cells derived from bone. J Biol Chem, 277: 26217-24, 2002. and MIP-1ß in the development of osteolytic lesions in multiple myeloma. Blood, 100: 2195-202, 2002. blocks bone destruction in a model of myeloma bone disease. J Clin Investig, 108: 1833-41, 2001.[CrossRef][Medline]
B. Blood, 87: 1104-12, 1996.This article has been cited by other articles:
|
|
 |
|
  Y.-W. Qiang, B. Hu, Y. Chen, Y. Zhong, B. Shi, B. Barlogie, and J. D. Shaughnessy Jr Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling Blood, April 30, 2009; 113(18): 4319 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sezer Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment Oncologist, March 1, 2009; 14(3): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth Blood, July 15, 2008; 112(2): 374 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, A. Pennisi, and S. Yaccoby Role of decorin in the antimyeloma effects of osteoblasts Blood, July 1, 2008; 112(1): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, and C. Pellat-Deceunynck Osteoclasts support the survival of human plasma cells in vitro Int. Immunol., June 1, 2008; 20(6): 775 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, P. Lin, Y. Shi, J. Romaguera, L. W. Kwak, et al. A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma Clin. Cancer Res., April 1, 2008; 14(7): 2154 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Neri, S. Kumar, M. T. Fulciniti, S. Vallet, S. Chhetri, S. Mukherjee, Y. Tai, D. Chauhan, P. Tassone, S. Venuta, et al. Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model Clin. Cancer Res., October 1, 2007; 13(19): 5903 - 5909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhan, S. Colla, X. Wu, B. Chen, J. P. Stewart, W. M. Kuehl, B. Barlogie, and J. D. Shaughnessy Jr CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms Blood, June 1, 2007; 109(11): 4995 - 5001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Bahlis, A. M. King, D. Kolonias, L. M. Carlson, H. Y. Liu, M. A. Hussein, H. R. Terebelo, G. E. Byrne Jr, B. L. Levine, L. H. Boise, et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival Blood, June 1, 2007; 109(11): 5002 - 5010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colla, F. Zhan, W. Xiong, X. Wu, H. Xu, O. Stephens, S. Yaccoby, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells Blood, May 15, 2007; 109(10): 4470 - 4477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood, March 1, 2007; 109(5): 2106 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, M. Abe, M. Hiasa, A. Oda, H. Amou, A. Nakano, K. Takeuchi, K. Kitazoe, S. Kido, D. Inoue, et al. Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin Clin. Cancer Res., February 1, 2007; 13(3): 816 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chatterjee, S. Jain, T. Stuhmer, M. Andrulis, U. Ungethum, R.-J. Kuban, H. Lorentz, K. Bommert, M. Topp, D. Kramer, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90{alpha} and {beta} in multiple myeloma cells, which critically contribute to tumor-cell survival Blood, January 15, 2007; 109(2): 720 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kukreja, A. Hutchinson, K. Dhodapkar, A. Mazumder, D. Vesole, R. Angitapalli, S. Jagannath, and M. V. Dhodapkar Enhancement of clonogenicity of human multiple myeloma by dendritic cells J. Exp. Med., August 7, 2006; 203(8): 1859 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yaccoby The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, and Apoptosis-Resistant Phenotype Clin. Cancer Res., November 1, 2005; 11(21): 7599 - 7606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Oshima, M. Abe, J. Asano, T. Hara, K. Kitazoe, E. Sekimoto, Y. Tanaka, H. Shibata, T. Hashimoto, S. Ozaki, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 Blood, November 1, 2005; 106(9): 3160 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature Blood, August 1, 2005; 106(3): 1021 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yin Chondroitin Synthase 1 Is a Key Molecule in Myeloma Cell-Osteoclast Interactions J. Biol. Chem., April 22, 2005; 280(16): 15666 - 15672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto and M. Abe The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions IBMS BoneKEy, February 1, 2005; 2(2): 7 - 10. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Roodman Osteoclasts and myeloma cells stick together Blood, October 15, 2004; 104(8): 2209 - 2209. [Full Text] [PDF]
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
